Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.
Pinter F, Papay J, Almasi A, Sapi Z, Szabo E, Kanya M, Tamasi A, Jori B, Varkondi E, Moldvay J, Szondy K, Keri G, Dominici M, Conte P, Eckhardt S, Kopper L, Schwab R, Petak I. Pinter F, et al. Among authors: petak i. J Mol Diagn. 2008 Mar;10(2):160-8. doi: 10.2353/jmoldx.2008.070125. Epub 2008 Feb 7. J Mol Diagn. 2008. PMID: 18258923 Free PMC article.
Functional evaluation of multidrug resistance transporter activity in surgical samples of solid tumors.
Schwab R, Micsik T, Szokolóczi O, Schafer E, Tihanyi B, Tihanyi T, Kupcsulik P, Diófalvi K, Mersich T, Besznyak I Jr, Zarand A, Mihalik R, Sarkadi B, Kéri G, Pap A, Jakab F, Kopper L, Petak I. Schwab R, et al. Among authors: petak i. Assay Drug Dev Technol. 2007 Aug;5(4):541-50. doi: 10.1089/adt.2007.067. Assay Drug Dev Technol. 2007. PMID: 17767422
Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone.
Balla P, Moskovszky L, Sapi Z, Forsyth R, Knowles H, Athanasou NA, Szendroi M, Kopper L, Rajnai H, Pinter F, Petak I, Benassi MS, Picci P, Conti A, Krenacs T. Balla P, et al. Among authors: petak i. Histopathology. 2011 Sep;59(3):376-89. doi: 10.1111/j.1365-2559.2011.03948.x. Histopathology. 2011. PMID: 22034878
Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.
Schwab R, Petak I, Kollar M, Pinter F, Varkondi E, Kohanka A, Barti-Juhasz H, Schönleber J, Brauswetter D, Kopper L, Urban L. Schwab R, et al. Among authors: petak i. Lung Cancer. 2014 Jan;83(1):109-11. doi: 10.1016/j.lungcan.2013.10.006. Epub 2013 Oct 19. Lung Cancer. 2014. PMID: 24192513
77 results